Biotechnology

Ironwood Pharmaceuticals appoints a veteran CMO and launches a key Phase 3 trial, signaling a strategic pivot beyond its blockbuster to conquer rare diseases.

A U.S.-China partnership is testing a drug that could replace cataract surgery. The ZOC2017217 eye drop aims to reverse vision loss for millions.

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.

Atrium Therapeutics' clinical trial for a rare cardiomyopathy isn't just a milestone; it's a strategic maneuver signaling the arrival of precision RNA therapies in cardiology.

Elevara Medicines taps biotech veteran Dr. Mai-Britt Zocca to lead its charge against rheumatoid arthritis with a novel drug and $70M in backing.

Erasca secures $550M to advance its attack on the notorious RAS/MAPK pathway. A look at the science, the strategy, and what it means for oncology.

Eupraxia Pharmaceuticals is overhauling its leadership and relocating to major biotech hubs, betting it all on its late-stage pipeline and a pivotal trial.

The German biotech has slashed its revenue forecast and now projects a major loss, sending a shockwave through the market and raising questions about its health.

A Norwegian biotech has dosed its first patient with a novel TCR-NK therapy, a potential breakthrough in delivering scalable, precise treatment for solid tumors.

A landmark public-private partnership in Vietnam pioneers bioengineered corneas, promising to restore sight to millions and signaling a new era for ASEAN biotech.

A new partnership aims to automate the complex manufacturing of Treg cell therapies, potentially unlocking a new treatment for severe rheumatoid arthritis.

With a new CMO, $50M in fresh capital, and pivotal trials on the horizon, Cue Biopharma makes a strategic bet on an immunology veteran to guide its future.

Voyager Therapeutics' new gene therapy just cleared a key FDA hurdle. With promising preclinical data, it's a major momentum signal in the fight against Alzheimer's.

By hiring top drug and deal makers, Bexorg signals its AI-powered human brain platform is ready to move from a bold experiment to a commercial powerhouse.

Alto Neuroscience's $100M raise fuels its quest to treat resistant depression. It's a high-stakes play on a biomarker-driven approach in a challenging field.

As BNB Plus Corp. falls from Nasdaq to the over-the-counter markets, its hybrid crypto-biotech model is under intense scrutiny. What does this mean for investors?

A Utah biotech is deploying UAE genomics and a novel drug to mimic natural immunity to Alzheimer's, signaling a strategic shift to precision prevention.

Ocugen inks a potential $255M+ deal to bring its OCU400 gene therapy for Retinitis Pigmentosa to the MENA region, a strategic move into a high-need market.

Delonix Bioworks is running parallel trials in China and Australia for its MenB vaccine, a strategic gambit that could disrupt a billion-dollar market.